Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactoplantibacillus plantarum CECT7529
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactoplantibacillus plantarum CECT7529** is a specific probiotic bacterial strain originally isolated and developed as a candidate for cholesterol-lowering interventions. It is part of a group of three closely related strains (CECT7527, CECT7528, CECT7529) often used in combination. This strain survives GI tract conditions, adheres to intestinal cells, exhibits high bile salt hydrolase activity (contributing to cholesterol deconjugation and removal), directly binds and assimilates cholesterol, and produces short-chain fatty acids such as propionic and butyric acids. CECT7529 in particular shows a high degree of these probiotic functionalities and has been studied alone and in combination for reduction of blood lipid levels, particularly LDL cholesterol. Clinical studies show good tolerability and significant cholesterol-lowering effects when combined with other CECT strains and/or monacolin K. The strain is developed and patented by AB-BIOTICS and marketed as part of AB-Life products, with capsule manufacturing by contract manufacturers such as Laboratorios Salvat.
- Brand names
- AB-Life
- Other names
- lactobacillus plantarum CECT7529
02
Targets
BSH (Bile salt hydrolase)
Beyond the preview
Go deeper on lactoplantibacillus plantarum CECT7529.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactoplantibacillus plantarum CECT7529.